ClinicaSpace.com
Clinical Research
News & Careers
 
Search the Site
    
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative Employers
  Post Job | Search Resumes | Login


By Industry | By Industry Segment | By Services and Suppliers | By Location | Profile Search
 Company Profile

 

Vertex Pharmaceuticals Incorporated 

130 Waverly Street

Cambridge  Massachusetts  02139-4242  U.S.A.
Phone: 617-444-6100 Fax: 617-444-6680


SEARCH JOBS




The Science of Possibility.

The first thing you’ll notice about Vertex is that we are not a conventional pharmaceutical company. Each and every person at Vertex is driven by a passion for fearless innovation and a bold desire to transform the lives of millions with new medicines. Together, by creating new possibilities in medicine, our employees are quite literally changing the world.

Vertex scientists and our collaborators are working on new medicines to advance the treatment of hepatitis C, cystic fibrosis, rheumatoid arthritis and other life-threatening diseases. Our development pipeline includes several investigational drugs that have the potential to transform the treatment of serious diseases. Every day brings us a step closer to getting patients the medicines they need and potentially changing their lives in previously unimaginable ways. It’s a demanding yet incredibly rewarding experience that cannot help but change your life in the process, too.

We employ more than 2,000 of the industry’s best and brightest people at locations around the world – all of us working toward tomorrow’s breakthrough medicines.

For more information on Vertex, please visit www.vrtx.com. For information on career opportunities with Vertex, please visit www.careers.vrtx.com..

Key Contacts:
Media: mediainfo@vrtx.com
Investors: investorinfo@vrtx.com
Patient Inquiries: clinical_trials@vrtx.com


This div will be replaced


 Key Statistics


Email:
Ownership: Public

Web Site: Vertex Pharmaceuticals (MA)
Employees: ~1000
Symbol: VRTX
 





Collaborations

Cystic Fibrosis Foundation Therapeutics, Inc.  (VX-770 for CF)

Kissei Pharmaceutical Co., Ltd.  (VX-702 for RA)

GlaxoSmithKline  (VX-409 and Backup Compounds)

Janssen Pharmaceutica N.V.  (telaprevir for HCV) - Europe, South America, Australia, the Middle East and other countries

Merck & Co., Inc.  (MK-0457 (VX-680), MK-6592 (VX-667) and VX-689 for Cancer)

Mitsubishi Pharma Corporation  (telaprevir for HCV) - Japan and certain Far East countries





 Company News
Vertex Pharmaceuticals (MA) (VRTX) Calls for Redemption of $400 Million in Convertible Senior Subordinated Notes Due 2015 5/17/2013 9:44:15 AM    More...
Vertex Pharmaceuticals (MA) (VRTX) CFO Rings Register on $35 Million Insider Sale 4/24/2013 8:17:49 AM    More...
Vertex Pharmaceuticals (MA) (VRTX) to Report First Quarter 2013 Financial Results on Tuesday, April 30 4/2/2013 6:35:23 AM    More...
Vertex Pharmaceuticals (MA) (VRTX) Nails Mid-Stage Study for Influenza 3/4/2013 10:39:11 AM    More...
Vertex Pharmaceuticals (MA) (VRTX) Release: Republic of Ireland Approves Funding for KALYDECO™ (ivacaftor), the First Medicine to Treat the Underlying Cause of Cystic Fibrosis, for People With a Specific Genetic Mutation (G551D) 2/1/2013 3:04:19 PM    More...
Vertex Pharmaceuticals (MA) (VRTX) Reports Full-Year and Fourth Quarter 2012 Financial Results and Provides Updates on Key Development Programs 1/30/2013 6:07:12 AM    More...
Vertex Pharmaceuticals (MA) (VRTX) to Report Fourth Quarter and Full Year 2012 Financial Results on Tuesday, January 29 1/16/2013 9:24:47 AM    More...
Vertex Pharmaceuticals (MA) (VRTX) Release: National Health Service in England Funds KALYDECO™ (ivacaftor), the First Medicine to Treat the Underlying Cause of Cystic Fibrosis, for People With a Specific Genetic Mutation (G551D) 12/19/2012 9:35:08 AM    More...
Cystic Fibrosis Drug From Vertex Pharmaceuticals (MA) (VRTX) is Approved by Canadian Regulators 12/3/2012 7:44:25 AM    More...
Vertex Pharmaceuticals (MA) (VRTX) Reports Third Quarter 2012 Financial Results and Recent Progress in Development Programs 11/2/2012 8:31:37 AM    More...
12345678910...